Use of a different tumor model, not targeting a ubiquitous antigen such as CD19 on B cells, could help to delineate if CD40L-modifed CAR T cells can prime CD8+ T cells via APC licensing at a local level. The gene discussed is CD8A; the disease is neoplasm.